Skip to main content
main-content

Genitourinary cancers

News and opinion

11-07-2019 | Prostate cancer | News

Conservative management increasing in younger prostate cancer patients

Rates of active surveillance or watchful waiting among younger men with low‐risk prostate cancer have quadrupled in recent years but remain below those for older men, despite no apparent increased mortality risk, research shows.

10-07-2019 | Castration-resistant prostate cancer | News

Glucocorticoid regimens explored in mCRPC

Combining abiraterone acetate with a relatively high dose of prednisone or dexamethasone may reduce mineralocorticoid excess toxic effects, but can result in increased metabolic toxicity, study data show.

04-07-2019 | Prostate cancer | News

EBRT has smallest impact on sexual function after prostate cancer diagnosis

Among the potential active treatment options for prostate cancer, external‐beam radiotherapy alone results in the best preservation of sexual function up to 2 years after treatment, population-based study data show.

01-07-2019 | Renal cell carcinoma | News

Targeted therapy can benefit complex patients with advanced RCC

Targeted therapy improves survival over nontargeted therapy among patients with metastatic renal cell carcinoma, including those who are older and have disabilities, shows an analysis of real-world data.

28-06-2019 | Immunotherapy | Highlight | News

Checkpoint inhibitor rechallenge feasible after irAE-related discontinuation

Two studies point to the feasibility of resuming immune checkpoint inhibitors in patients who discontinue treatment due to immune-related adverse events.

26-06-2019 | Renal cell carcinoma | News

Nivolumab has ‘limited’ CNS activity in RCC patients with brain metastases

In patients with clear cell renal cell carcinoma and untreated central nervous system metastases, intracranial response to nivolumab monotherapy is restricted to those with a limited tumor burden, suggest phase II findings.

25-06-2019 | Renal cell carcinoma | ASCO 2019 | News

JAVELIN Renal 101 biomarker analysis may help personalize patient care

Biomarker analysis has given fresh insight into the response achieved with avelumab plus axitinib among advanced renal cell carcinoma patients participating in the JAVELIN Renal 101 trial.

21-06-2019 | Castration-resistant prostate cancer | ASCO 2019 | News

Race-based difference in survival with sipuleucel-T therapy confirmed

Following treatment with the autologous cellular immunotherapy sipuleucel-T for metastatic castration-resistant prostate cancer, African–American men can expect to live longer than their Caucasian counterparts, indicates an analysis of the PROCEED registry.

18-06-2019 | Renal cell carcinoma | ASCO 2019 | News

Sarcomatoid RCC patients benefit from immune checkpoint inhibitor therapy

Subgroup analysis of the IMmotion151 trial suggests improved survival with first-line atezolizumab plus bevacizumab versus sunitinib for locally advanced or metastatic renal cell carcinoma patients with sarcomatoid differentiation.

17-06-2019 | Urothelial cancer | ASCO 2019 | News

Bevacizumab adds no value to chemotherapy for metastatic urothelial cancer

Adding bevacizumab to gemcitabine plus cisplatin chemotherapy does not improve overall survival when used as first-line therapy for metastatic urothelial carcinoma, show results of the phase III CALGB 90601 study.

14-06-2019 | Castration-sensitive prostate cancer | ASCO 2019 | News

ENZAMET supports enzalutamide use in men with metastatic CSPC

Men with metastatic castration-sensitive prostate cancer derive a significant overall survival benefit from the addition of enzalutamide to standard testosterone suppression, show phase III trial results.

09-06-2019 | Renal cell carcinoma | ASCO 2019 | News

KEYNOTE-426 subgroup analyses confirm pembrolizumab–axitinib efficacy

Research presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, adds support for use of pembrolizumab plus axitinib  as a first-line treatment for patients with metastatic renal cell carcinoma.

05-06-2019 | Urothelial cancer | ASCO 2019 | News

Positive phase II findings for enfortumab vedotin in advanced urothelial cancer

Preliminary results from a pivotal trial of enfortumab vedotin, an antibody–drug conjugate targeting Nectin-4, show a “clinically meaningful” response in patients with unresectable locally advanced or metastatic urothelial cancer.

04-06-2019 | Castration-resistant prostate cancer | ASCO 2019 | News

Metformin addition ruled out for nondiabetic men with metastatic CRPC

The outcomes of nondiabetic men with metastatic castration-resistant prostate cancer are not improved with the addition of metformin to docetaxel, finds the French TAXOMET trial.

03-06-2019 | Castration-resistant prostate cancer | ASCO 2019 | News

Olaparib response may depend on DDR mutation type in mCRPC

The degree of response to olaparib among patients with heavily pretreated metastatic castration-resistant prostate cancer varies according to the type of DNA damage repair alteration the tumor carries, research shows.

02-06-2019 | Castration-sensitive prostate cancer | ASCO 2019 | News

TITAN: OS benefit seen with apalutamide in metastatic CSPC setting

Supplementing androgen deprivation therapy with apalutamide leads to significant improvements in survival outcomes in men with metastatic castration-sensitive prostate cancer, show phase III trial results.

01-06-2019 | Castration-resistant prostate cancer | ASCO 2019 | News

ARAMIS QoL results add support for darolutamide in nonmetastatic CRPC

Men with nonmetastatic castration-resistant prostate cancer enrolled in the ARAMIS trial report favorable quality of life outcomes with darolutamide relative to placebo.

30-05-2019 | Urothelial cancer | News

AE link to response shown in PD-1/PD-L1 inhibitor-treated urothelial cancer

Individuals with urothelial cancer who respond to treatment with PD-1 or PD-L1 inhibitors are more likely to report adverse events of special interest, including immune-mediated events, than nonresponders, results of a pooled analysis show.

28-05-2019 | Prostate cancer | Highlight | News

Socioeconomic factors major players in prostate cancer racial disparity

Research published in JAMA Oncology confirms that prostate cancer-specific mortality is not significantly different between Black and White men with nonmetastatic disease when access to care and treatment is comparable.

23-05-2019 | Urothelial cancer | News

Sustained nivolumab, ipilimumab activity shown in advanced urothelial cancer

Extended follow-up of patients with unresectable locally advanced or metastatic urothelial carcinoma in the CheckMate 032 trial shows sustained antitumor activity of nivolumab alone and in combination with ipilimumab.

Image Credits